Alkermes (ALKS) Reports Early ADHD Drug Results. Can a Larger Trial Show it Works?

Alkermes plc (NASDAQ:ALKS) reported on September 21 that adults receiving the investigational oral drug ALKS 7290 showed improved symptoms of attention-deficit hyperactivity disorder (ADHD). After 14 days, median reductions on the Adult ADHD Investigator Symptom Rating Scale were 14 points at a total daily dose of 20 mg and 19 points at 50 mg. Both regimens used split doses.

The 50-participant Phase 1b trial included placebo, but those figures measure changes from patients’ starting scores. Safety and tolerability were the primary objectives. For Alkermes plc (NASDAQ:ALKS), the results support further testing while leaving the size of any benefit over placebo unresolved.

Read Also: Viatris (VTRS) Wins Japan WAKIX Approval. Can it Build a Meaningful Specialty Business?

Bull Case

ALKS 7290 activates orexin 2 receptors, part of a brain signaling system involved in wakefulness and attention. Alkermes plc (NASDAQ:ALKS) is testing whether this approach can address ADHD alongside its broader work in sleep disorders. Success would expand the commercial possibilities of the orexin portfolio into another treatment setting.

For Alkermes plc (NASDAQ:ALKS), an additional treatment mechanism could matter if it offers patients a useful balance of symptom control and tolerability. A different biological target creates room for differentiation, although the larger study must establish what patients actually gain.

Alkermes plc (NASDAQ:ALKS) also has an established business behind its development effort. Second-quarter revenue totaled $496.0 million, while company-wide research and development expense was $112.9 million. A successful ADHD program could add another future product to that business and improve the return on its research investment.

Take a look at: Xenon Pharmaceuticals (XENE) Seeks Epilepsy Approval. Can its Drug Overcome a Depression Setback?

Bear Case

The trial was not designed or powered to establish statistically significant differences between treatment groups. Alkermes plc (NASDAQ:ALKS) did not report a placebo-adjusted symptom benefit. Improvement from baseline can include effects unrelated to the drug, so the headline reductions cannot establish how much improvement treatment itself caused.

The larger reduction at 50 mg is worth investigating, but it does not establish that the higher dose works better. For Alkermes plc (NASDAQ:ALKS), dose selection must balance efficacy with side effects. No serious treatment-emergent adverse events or treatment-group discontinuations were reported; common adverse events included insomnia, urinary symptoms, and dizziness. Two weeks of treatment cannot establish long-term safety or sustained symptom control.

Alkermes plc (NASDAQ:ALKS) must also translate results from a short inpatient study into a treatment patients can use consistently in daily life. Even a positive efficacy result would leave questions about durability, dosing convenience, and positioning against existing therapies. Those factors will influence eventual adoption and pricing.

Hedge Fund Sentiment

The filings available so far reflect positions held before Alkermes plc (NASDAQ:ALKS) reported its early ADHD trial results. Insider Monkey’s database showed 55 hedge funds holding Alkermes plc (NASDAQ:ALKS) at the end of 2Q2026, down from 56 funds three months earlier.

Conclusion

Alkermes plc (NASDAQ:ALKS) has a credible reason to continue development. The enrolling Phase 2 trial targets approximately 312 participants and will compare symptom-score changes with placebo at four weeks, with results expected in 2027. The decisive evidence will be the size of that difference, consistency across doses, and tolerability. A clear benefit over placebo would strengthen the case for further investment in ADHD. Longer-term results would then need to support a treatment profile that physicians and patients find useful.

READ NEXT: Pan American Silver (PAAS) Updates its Reserve Base. How Much Growth Reflects Better Mines? and Lennar (LEN) Cuts Delivery Forecast. Can Construction Savings Offset Heavy Incentives?

This article is originally published at Insider Monkey.